Variants of SARS-CoV-2

Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)

Friday, June 11, 2021 - 7:00am

(*2) Subject microorganisms: SARS-CoV-2 (3 strains above) provided by the National Institute of Infectious Diseases.

Key Points: 
  • (*2) Subject microorganisms: SARS-CoV-2 (3 strains above) provided by the National Institute of Infectious Diseases.
  • In this study, the one purchased from the JCRB Cell Bank, the National Institutes of Biomedical Innovation, Health and Nutrition, was used.
  • (*6) N501Y variant: 501st amino acid of S protein is replaced from aspartic acid (N) to tyrosine (Y).
  • Compared to the conventional strains, this variant may work as a stronger suppressor of the immune system and vaccination efficiency.

Sixth Wave Detects UK and South African Variants of SARS-CoV-2

Thursday, June 10, 2021 - 12:00pm

The virus variants detected include the UK variant and the South African variant.

Key Points: 
  • The virus variants detected include the UK variant and the South African variant.
  • There are documented cases of new variants circumventing the human immune system and causing reinfection and drastically reduced efficacy of certain vaccines.
  • Sixth Wave continues to expand the capabilities of the AMIP diagnostic platform as it works on improving the specificity and sensitivity in their prototype devices.
  • Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries.

New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern

Wednesday, June 9, 2021 - 12:15pm

The study provides further evidence that the T-cell response may contribute to protection from COVID-19.

Key Points: 
  • The study provides further evidence that the T-cell response may contribute to protection from COVID-19.
  • In the multinational phase 3 ENSEMBLE trial, participants given Johnson & Johnsons vaccine experienced similar efficacy against the B.1.351 variant.
  • Mapping exactly how the variants impact different parts of the virus can indicate if the immune response is likely to be affected.
  • The tool can be used to study the T-cell immune response for vaccine research across COVID-19 variants., mapping across >160KSARS-CoV-2-specific antigen-TCR sequence-level data.

Twist Bioscience Begins Shipping of Synthetic RNA Controls for Kappa (B.1.617.1) SARS-CoV-2 Variants for Development of Accurate Tests

Tuesday, June 8, 2021 - 1:00pm

The company is also working on controls for the SARS-CoV-2 Delta (B.1.617.2) and B.1.617.3 variants.

Key Points: 
  • The company is also working on controls for the SARS-CoV-2 Delta (B.1.617.2) and B.1.617.3 variants.
  • Unfortunately, India is experiencing a massive outbreak and overwhelming challenge with new viral variants and a largely unvaccinated population.
  • The Twist synthetic controls are designed based on specific SARS-CoV-2 variants, cover the full viral genome and are sequence-verified.
  • For customers interested in alternative variants of SARS-CoV-2, or synthetic RNA or DNA controls for other sequences, Twist can provide custom controls in multiple formats.

Eurofins Launches a New Multiplex PCR Assay for Rapid Detection of the B.1.617 “India” SARS-CoV-2 Variant

Thursday, June 3, 2021 - 6:15am

Eurofins Technologies (Paris:ERF) announces the launch of its GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 Variants of Concern including B.1.617 (India), B.1.427/B.1.429 (California/USA), B.1.351 (South Africa) or P.1 (Brazil).

Key Points: 
  • Eurofins Technologies (Paris:ERF) announces the launch of its GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 Variants of Concern including B.1.617 (India), B.1.427/B.1.429 (California/USA), B.1.351 (South Africa) or P.1 (Brazil).
  • The assay facilitates the identification of the relevant mutations E484Q, E484K and L452R in one reaction combined with the simultaneous discrimination from the S gene E484 wildtype variant.
  • These mutations have been associated with reports of potential decreased efficacy of certain vaccines and an increase in the transmissibility of the virus.
  • Eurofins Technologies is committed to continue to rapidly adapt its product offering to the meet the evolving challenges of SARS-CoV-2.

Scripps Research Institute testing shows Viraleze highly active against UK COVID strain

Tuesday, June 1, 2021 - 10:03am

Starpharma is alsotesting the Japan/Brazil and South African variants of COVID, with the results expected in the coming weeks.

Key Points: 
  • Starpharma is alsotesting the Japan/Brazil and South African variants of COVID, with the results expected in the coming weeks.
  • The antiviral testing was conducted by the renowned Scripps Research Institute in the US, with the UK variant of SARS-CoV-2, which has been classified as a variant of concern.
  • The UK variant was recently reported to be responsible for over 98% of the positive COVID infections in England and linked to multiple outbreaks worldwide.
  • Viraleze is registered for sale in Europe and the UK, and is available through one of the UK's largest pharmacy chains, LloydsPharmacy.

Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19

Wednesday, May 26, 2021 - 11:03pm

This includes, for example, individuals who are 65 years of age and older or individuals who have certain medical conditions.

Key Points: 
  • This includes, for example, individuals who are 65 years of age and older or individuals who have certain medical conditions.
  • "It is important to expand the arsenal of monoclonal antibody therapies that are expected to retain activity against the circulating variants of COVID-19 in the United States."
  • Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful antigens such as viruses.
  • The FDA is carefully monitoring circulating viral variants and their sensitivity to monoclonal antibodies authorized to treat COVID-19, including sotrovimab.

Eurofins Expands Its Global Sequencing and Mutation-Specific PCR Capabilities to Detect COVID-19 Variants of Concern and of Interest

Tuesday, May 25, 2021 - 6:20am

Eurofins (Paris:ERF) continues to develop innovative COVID-19 testing solutions and has now reached two important milestones.

Key Points: 
  • Eurofins (Paris:ERF) continues to develop innovative COVID-19 testing solutions and has now reached two important milestones.
  • Eurofins ARTIC SARS-CoV-2 Whole Genome Sequencing service includes NGS and detailed reporting for universal end-to-end surveillance of pandemic development, tracking the emergence and dynamics of existing and new mutational Variants of Concern.
  • This enables accurate lineage and variant identification and surveillance of emerging and spreading Variants of Concern.
  • Eurofins has also reached the milestone of over 24 million COVID-19 PCR tests completed since the start of the pandemic.

Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants

Monday, May 24, 2021 - 12:00pm

Interferon beta ('IFN-beta') is a naturally-occurring protein, which orchestrates the body's antiviral responses by triggering the production of hundreds of antiviral proteins which act across the viral replication cycle to confer broad-spectrum antiviral activity.

Key Points: 
  • Interferon beta ('IFN-beta') is a naturally-occurring protein, which orchestrates the body's antiviral responses by triggering the production of hundreds of antiviral proteins which act across the viral replication cycle to confer broad-spectrum antiviral activity.
  • In vitro experiments were conducted at Viroclinics-DDL in the Netherlands to confirm that SNG001 had activity against the B.1.1.7 (UK or Kent) and B.1.351 (South African) variants.
  • Concentrations, readily achievable following inhaled delivery of interferon beta, that gave 90% inhibition (IC90) were 3.2, 4.0 and 3.4 IU/mL respectively.
  • Richard Marsden, CEO of Synairgen, added: As expected, these data confirm that SNG001 is a broad-spectrum antiviral product, now also demonstrating applicability against SARS-CoV-2 variants.

Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants

Monday, May 24, 2021 - 7:00am

Interferon beta ('IFN-beta') is a naturally-occurring protein, which orchestrates the body's antiviral responses by triggering the production of hundreds of antiviral proteins which act across the viral replication cycle to confer broad-spectrum antiviral activity.

Key Points: 
  • Interferon beta ('IFN-beta') is a naturally-occurring protein, which orchestrates the body's antiviral responses by triggering the production of hundreds of antiviral proteins which act across the viral replication cycle to confer broad-spectrum antiviral activity.
  • In vitro experiments were conducted at Viroclinics-DDL in the Netherlands to confirm that SNG001 had activity against the B.1.1.7 (UK or Kent) and B.1.351 (South African) variants.
  • Concentrations, readily achievable following inhaled delivery of interferon beta, that gave 90% inhibition (IC90) were 3.2, 4.0 and 3.4 IU/mL respectively.
  • Richard Marsden, CEO of Synairgen, added: As expected, these data confirm that SNG001 is a broad-spectrum antiviral product, now also demonstrating applicability against SARS-CoV-2 variants.